Literature DB >> 16424516

Which treatment is best for which AMD patient?

P Kroll, C H Meyer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16424516      PMCID： PMC1860157          DOI： 10.1136/bjo.2005.083337

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  29 in total

1.  Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; Andrew A Moshfeghi; Carmen A Puliafito
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2005 Jul-Aug

2.  Functional changes after photodynamic therapy with verteporfin.

Authors:  Carsten H Meyer; Deborah J Lapolice; Sharon Fekrat
Journal:  Am J Ophthalmol       Date:  2005-01       Impact factor: 5.258

3.  Chorioretinal temperature monitoring during transpupillary thermotherapy for choroidal neovascularisation.

Authors:  S Miura; H Nishiwaki; Y Ieki; Y Hirata; Y Honda; Y Sugino; Y Okazaki
Journal:  Br J Ophthalmol       Date:  2005-04       Impact factor: 4.638

4.  New treatments for age-related macular degeneration.

Authors:  Andrew P Schachat
Journal:  Ophthalmology       Date:  2005-04       Impact factor: 12.079

5.  Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration.

Authors:  C Eckardt; U Eckardt; H G Conrad
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1999-04       Impact factor: 3.117

Review 6.  Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update.

Authors: 
Journal:  Retina       Date:  2005 Feb-Mar       Impact factor: 4.256

7.  Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey.

Authors:  Deeba Husain; Ivana Kim; Danny Gauthier; Anne Marie Lane; Miltiadis K Tsilimbaris; Eric Ezra; Edward J Connolly; Norman Michaud; Evangelos S Gragoudas; Charles A O'Neill; Joseph C Beyer; Joan W Miller
Journal:  Arch Ophthalmol       Date:  2005-04

8.  Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no. 12.

Authors:  Päivi H Miskala; Eric B Bass; Neil M Bressler; Ashley L Childs; Barbara S Hawkins; Carol M Mangione; Marta J Marsh
Journal:  Ophthalmology       Date:  2004-11       Impact factor: 12.079

9.  Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization.

Authors:  Richard F Spaide; John Sorenson; Leandro Maranan
Journal:  Ophthalmology       Date:  2005-02       Impact factor: 12.079

10.  [Transient visual decrease after photodynamic therapy].

Authors:  S Mennel; N Hausmann; C H Meyer; S Hörle; S Peter
Journal:  Ophthalmologe       Date:  2005-01       Impact factor: 1.059
View more
  10 in total

1.  [Ocular pharmacokinetics: Topical, intravitreal, and systemic drug application].

Authors:  C H Meyer; T U Krohne
Journal:  Ophthalmologe       Date:  2014-02       Impact factor: 1.059

2.  Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis.

Authors:  Xiao-Yu Zhang; Xiao-Fan Guo; Shao-Dan Zhang; Jing-Na He; Cao-Yu Sun; Yin Zou; Han-Si Bi; Yang Qu
Journal:  Int J Ophthalmol       Date:  2014-04-18       Impact factor: 1.779

3.  Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Multifocal-ERG after use of bevacizumab in ARMD.

Authors:  Marilita M Moschos; Dimitrios Brouzas; Michael Apostolopoulos; Chrysanthi Koutsandrea; Eleni Loukianou; Michael Moschos
Journal:  Doc Ophthalmol       Date:  2007-01-10       Impact factor: 2.379

4.  Multifocal electroretinogram findings after intravitreal bevacizumab injection in choroidal neovascularization of age-related macular degeneration.

Authors:  Joo Youn Park; Seung Hoon Kim; Tae Kwann Park; Young-Hoon Ohn
Journal:  Korean J Ophthalmol       Date:  2011-05-24

Review 5.  Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab.

Authors:  C H Meyer; F G Holz
Journal:  Eye (Lond)       Date:  2011-04-01       Impact factor: 3.775

6.  Experimental study on the photodynamic treatment of choroidal neovasculization with nanophthalocyanine photosensitizer.

Authors:  Song-Yi Wu; Guo-Xing Xu; Yi-Ru Peng; Xiao-Fang Zhou; Jian Guo
Journal:  Int J Ophthalmol       Date:  2011-12-18       Impact factor: 1.779

7.  Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration.

Authors:  C H Meyer; S Mennel; J C Schmidt; P Kroll
Journal:  Br J Ophthalmol       Date:  2006-09       Impact factor: 4.638

8.  Effects of photodynamic therapy on the choriocapillaris and retinal pigment epithelium in the irradiated area.

Authors:  Nadia Artha Dewi; Mitsuko Yuzawa; Kasumi Tochigi; Akiyuki Kawamura; Ryusaburo Mori
Journal:  Jpn J Ophthalmol       Date:  2008-09-05       Impact factor: 2.447

Review 9.  [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series].

Authors:  C H Meyer; H-M Helb; N Eter
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

Review 10.  The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice.

Authors:  Nazimul Hussain; Yashoda Ghanekar; Inderjeet Kaur
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.